These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 18642142)

  • 1. Unique/major human metabolites: why, how, and when to test for safety in animals.
    Luffer-Atlas D
    Drug Metab Rev; 2008; 40(3):447-63. PubMed ID: 18642142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development.
    Peck CC; Barr WH; Benet LZ; Collins J; Desjardins RE; Furst DE; Harter JG; Levy G; Ludden T; Rodman JH
    J Clin Pharmacol; 1994 Feb; 34(2):111-9. PubMed ID: 8163710
    [No Abstract]   [Full Text] [Related]  

  • 3. Regulatory considerations for preclinical development of anticancer drugs.
    DeGeorge JJ; Ahn CH; Andrews PA; Brower ME; Giorgio DW; Goheer MA; Lee-Ham DY; McGuinn WD; Schmidt W; Sun CJ; Tripathi SC
    Cancer Chemother Pharmacol; 1998; 41(3):173-85. PubMed ID: 9443633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early microdose drug studies in human volunteers can minimise animal testing: Proceedings of a workshop organised by Volunteers in Research and Testing.
    Combes RD; Berridge T; Connelly J; Eve MD; Garner RC; Toon S; Wilcox P
    Eur J Pharm Sci; 2003 May; 19(1):1-11. PubMed ID: 12729856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Innovative early development regulatory approaches: expIND, expCTA, microdosing.
    Robinson WT
    Clin Pharmacol Ther; 2008 Feb; 83(2):358-60. PubMed ID: 18091759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How pharmacogenomics will impact the federal regulation of clinical trials and the new drug approval process.
    Binzak BA
    Food Drug Law J; 2003; 58(1):103-27. PubMed ID: 12739592
    [No Abstract]   [Full Text] [Related]  

  • 7. Meeting the MIST regulations: human metabolism in Phase I using AMS and a tiered bioanalytical approach.
    Lappin G; Seymour M; Gross G; Jørgensen M; Kall M; Kværnø L
    Bioanalysis; 2012 Feb; 4(4):407-16. PubMed ID: 22394141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 0 trials: a platform for drug development?
    Lancet; 2009 Jul; 374(9685):176. PubMed ID: 19616703
    [No Abstract]   [Full Text] [Related]  

  • 9. Oncology's first Phase 0 trial.
    Rowan K
    J Natl Cancer Inst; 2009 Jul; 101(14):978-9. PubMed ID: 19584322
    [No Abstract]   [Full Text] [Related]  

  • 10. Toxicology testing in drug discovery and development.
    Dorato MA; Buckley LA
    Curr Protoc Toxicol; 2007 Feb; Chapter 19():Unit19.1. PubMed ID: 23045141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An FDA oncology view of juvenile animal studies in support of initial pediatric trials for anticancer drugs.
    Leighton JK; Saber H; Reaman G; Pazdur R
    Regul Toxicol Pharmacol; 2016 Aug; 79():142-143. PubMed ID: 26952647
    [No Abstract]   [Full Text] [Related]  

  • 12. The human food safety evaluation of new animal drugs.
    Friedlander LG; Brynes SD; Fernández AH
    Vet Clin North Am Food Anim Pract; 1999 Mar; 15(1):1-11, vii. PubMed ID: 10088208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials.
    Marchetti S; Schellens JH
    Br J Cancer; 2007 Sep; 97(5):577-81. PubMed ID: 17726450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Causality Assessment in Premarketing Drug Clinical Trials: Regulatory Evolution in the USA and Ongoing Concerns.
    Goldman SA
    Drug Saf; 2016 Oct; 39(10):895-901. PubMed ID: 27473417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pragmatic approaches to determine the exposures of drug metabolites in preclinical and clinical subjects in the MIST evaluation of the clinical development phase.
    Haglund J; Halldin MM; Brunnström A; Eklund G; Kautiainen A; Sandholm A; Iverson SL
    Chem Res Toxicol; 2014 Apr; 27(4):601-10. PubMed ID: 24593263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006.
    Wang Y; Bhattaram AV; Jadhav PR; Lesko LJ; Madabushi R; Powell JR; Qiu W; Sun H; Yim DS; Zheng JJ; Gobburu JV
    J Clin Pharmacol; 2008 Feb; 48(2):146-56. PubMed ID: 18199891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory Forum Opinion Piece: Review of FDA Draft Guidance Testicular Toxicity-Evaluation during Drug Development Guidance for Industry.
    Hukkanen RR; Halpern WG; Vidal JD
    Toxicol Pathol; 2016 Oct; 44(7):927-30. PubMed ID: 27357192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolites in safety testing.
    Robison TW; Jacobs A
    Bioanalysis; 2009 Oct; 1(7):1193-200. PubMed ID: 21083045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.